Cyteir Therapeutics F1R15XK36 Bond
CYTDelisted Stock | USD 2.76 0.01 0.36% |
Cyteir Therapeutics holds a debt-to-equity ratio of 0.017. . Cyteir Therapeutics' financial risk is the risk to Cyteir Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Cyteir Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cyteir Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cyteir Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cyteir Therapeutics' stakeholders.
For most companies, including Cyteir Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cyteir Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cyteir Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Cyteir |
Given the importance of Cyteir Therapeutics' capital structure, the first step in the capital decision process is for the management of Cyteir Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Cyteir Therapeutics to issue bonds at a reasonable cost.
Popular Name | Cyteir Therapeutics BNP Paribas FRN |
Equity ISIN Code | US23284P1030 |
Bond Issue ISIN Code | USF1R15XK367 |
S&P Rating | Others |
Maturity Date | 31st of December 99 |
Issuance Date | Others |
Cyteir Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
BNP Paribas FRN | USF1R15XK367 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning Cyteir Therapeutics Use of Financial Leverage
Cyteir Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Cyteir Therapeutics' current equity. If creditors own a majority of Cyteir Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Cyteir Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company was incorporated in 2012 and is based in Lexington, Massachusetts. Cyteir Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.